{Reference Type}: Consensus Development Conference
{Title}: [Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in spondyloarthritis except for psoriatic arthritis].
{Author}: Juanola Roura X;Zarco Montejo P;Sanz Sanz J;Muñoz Fernández S;Mulero Mendoza J;Linares Ferrando LF;Gratacós Masmitja J;García de Vicuña R;Fernandez Carballido C;Collantes Estevez E;Batlle Gualda E;Ariza Ariza R;Loza Santamaría E;
{Journal}: Reumatol Clin
{Volume}: 7
{Issue}: 2
{Year}: Mar-Apr 2011
暂无{DOI}: 10.1016/j.reuma.2010.12.002
{Abstract}: <B>OBJECTIVE: </B>Due to the amount and variability in quality regarding the use of biologic therapy (BT) in patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA) patients, the Spanish Society of Rheumatology has promoted the generation of recommendations based on the best evidence available. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA), who are using, or about to use BT.<BR><B>METHODS: </B>Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique.<BR><B>RESULTS: </B>We have produced recommendations on the use of BT currently available for SpA (but not PsA) in our country. These recommendations include disease assessment, treatment objectives, therapeutic scheme and switching.<BR><B>CONCLUSIONS: </B>We present an update on the SER recommendations for the use of BT in patients with SpA, except for PsA.